Skip to main content
SpringerLink
Log in

Zoledronic acid induces apoptosis via stimulating the expressions of ERN1, TLR2, and IRF5 genes in glioma cells

  • Original Article
  • Published:
Tumor Biology

Abstract

Glioblastoma multiforme (GBM) is the most common and aggressive brain tumor that affects older people. Although the current therapeutic approaches for GBM include surgical resection, radiotherapy, and chemotherapeutic agent temozolomide, the median survival of patients is 14.6 months because of its aggressiveness. Zoledronic acid (ZA) is a nitrogen-containing bisphosphonate that exhibited anticancer activity in different cancers. The purpose of this study was to assess the potential effect of ZA in distinct signal transduction pathways in U87-MG cells. In this study, experiments performed on U87-MG cell line (Human glioblastoma-astrocytoma, epithelial-like cell line) which is an in vitro model of human glioblastoma cells to examine the cytotoxic and apoptotic effects of ZA. IC50 dose of ZA, 25 μM, applied on U87-MG cells during 72 h. ApoDIRECT In Situ DNA Fragmentation Assay was used to investigate apoptosis of U87MG cells. The quantitative reverse transcription polymerase chain reaction (qRT-PCR) (LightCycler480 System) was carried out for 48 gene expression like NF-κB, Toll-like receptors, cytokines, and inteferons. Our results indicated that ZA (IC50 dose) increased apoptosis 1.27-fold in U87MG cells according to control cells. According to qRT-PCR data, expression levels of the endoplasmic reticulum-nuclei-1 (ERN1), Toll-like receptor 2 (TLR2), and human IFN regulatory factor 5 (IRF5) tumor suppressor genes elevated 2.05-, 2.08-, and 2.3-fold by ZA, respectively, in U87MG cells. Our recent results indicated that ZA have a key role in GBM progression and might be considered as a potential agent in glioma treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Parsons DW, Jones S. X Zhang et al. An Integrated Genomic Analysis of Human Glioblastoma Multiforme: Science; 2008. doi:10.1126/science.1164382.

    Google Scholar 

  2. Bayin NS, Modrek AS, Placantonakis DG. Glioblastoma stem cells: molecular characteristics and therapeutic implications. World J Stem Cells. 2014;6(2):230–8.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Olar A, Aldape KD. Using the molecular classification of glioblastoma to inform personalized treatment. J Pathol. 2014;232:165–77.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Ramirez YP, Weatherbee JL, Wheelhouse RT, Ross AH. Glioblastoma multiforme therapy and mechanisms of resistance. Pharmaceuticals. 2013;6:1475–506.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. European organisation for research and treatment of cancer brain tumor and Radiotherapy groups, national cancer ınstitute of canada clinical trials group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. NEngl J Med. 2005;352:987–96.

    Article  CAS  Google Scholar 

  6. Okamoto S, Kawamura K, Quanhai L, Yamanaka M, Yang S, Fukamachi T, et al. Zoledronic acid produces antitumor effects on Mesothelioma through Apoptosis and S-phase arrest in p53-ındependent and Ras prenylation-ındependent manners. J Thorac Oncol. 2012;7:873–82.

    Article  CAS  PubMed  Google Scholar 

  7. Tamura T, Shomori K, Nakabayashi M, Fujii N, Ryoke K, Ito H. Zoledronic acid, a third-generation bisphosphonate, inhibits cellular growth and induces apoptosis in oral carcinoma cell lines. Oncol Rep. 2011;25:1139–43.

    Article  CAS  PubMed  Google Scholar 

  8. Verhulst A, Sun S, McKenna CE, D’Haese PC. Endocytotic uptake of Zoledronic acid by tubular cells may explain ıts renal effects in cancer patients receiving high doses of the compound. PLoS One. 2015;10(3):e0121861.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Morgan G, Lipton A. Antitumor effects and anticancer applications of bisphosphonates. Semin Oncol. 2010;37 Suppl 2:S30–40.

    Article  CAS  PubMed  Google Scholar 

  10. Gallo M, De Luca A, Lamura L, Normanno N. Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancer. Ann Oncol. 2012;23:597–604.

    Article  CAS  PubMed  Google Scholar 

  11. Stresing V, Daubine F, Benzaid I, Mönkkönen H, Clezardin P. Bisphosphonates in cancer therapy. Cancer Lett. 2007;257:16–35.

    Article  CAS  PubMed  Google Scholar 

  12. Gnant M, Clezardin P. Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature. Cancer Treat Rev. 2012;38:407–15.

    Article  CAS  PubMed  Google Scholar 

  13. Coleman RE. Skeletal complications of malignancy. Cancer. 1997;80:1588–94.

    Article  CAS  PubMed  Google Scholar 

  14. Timothy MF. The role of Bisphosphonates in the management of patients that have cancer. Vet Clin Small Anim. 2007;37:1091–110.

    Article  Google Scholar 

  15. Mahtani R, Jahanzeb M. Bisphosphonates as anticancer therapy for early breast cancer. Clinical Breast Cancer. 2010;10(5):359–66.

    Article  CAS  PubMed  Google Scholar 

  16. Neville-Webbe HL, Gnant M, Coleman RE. Potential anticancer properties of Bisphosphonates. Semin Oncol. 2010;37 Suppl 1:S53–65.

    Article  CAS  PubMed  Google Scholar 

  17. Singh T, Kaur V, Kumar M, Kaur P, Murthy RSR, Rawal RK. The critical role of bisphosphonates to target bone cancer metastasis: an overview. J Drug Target. 2015;23(1):1–15.

    Article  CAS  PubMed  Google Scholar 

  18. Chang J, Wang W, Zhang H, Hu Y, Yin Z. Bisphosphonates regulate cell proliferation, apoptosis and pro-osteoclastic expression in MG-63 human osteosarcoma cells. Oncol Lett. 2012;4:299–304.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Berenson JR. Antitumor effects of bisphosphonates: from the laboratory to the clinic. Curr Opin Support and Palliat Care. 2011;5:233–40.

    Article  Google Scholar 

  20. Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer. 2000;82:1459–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Nakajima H, Magae J, Tsuruga M, Sakaguchi K, Fujiwara I, Mizuta M, et al. Induction of mitochondria-dependent apoptosis through the inhibition of mevalonate pathway in human breast cancer cells by YM529, a new third generation bisphosphonate. Cancer Lett. 2007;253:89–96.

    Article  CAS  PubMed  Google Scholar 

  22. Sewing L, Steinberg F, Schmidt H, Goke R. The bisphosphonate zoledronic acid inhibits the growth of HCT-116 colon carcinoma cells and induces tumor cell apoptosis. Apoptosis. 2008;13:782–9.

    Article  CAS  PubMed  Google Scholar 

  23. Coxon JP, Oades GM, Kirby RS, Colston KW. Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation. B J U Int. 2004;94:164–70.

    Article  CAS  Google Scholar 

  24. Shipman CM, Croucher PI, Russell RG, Helfrich MH, Rogers MJ. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res. 1998;58:5294–7.

    CAS  PubMed  Google Scholar 

  25. Green J, Lipton A. Anticancer properties of zoledronic acid. Cancer Investig. 2010;28:944–57.

    Article  CAS  Google Scholar 

  26. Marra M, Abbruzzese A, Addeo R, Del Prete S, Tassone P, Tonini G, et al. Cutting the limits of aminobisphosphonates: new strategies for the potentiation of their anti-tumour effects. Curr Cancer Drug Targets. 2009;9:791–800.

    Article  CAS  PubMed  Google Scholar 

  27. Yuasa T, Kimura S, Ashihara E, Habuchi T, Maekawa T. Zoledronic acid - a multiplicity of anti-cancer action. Curr Med Chem. 2007;14:2126–35.

    Article  CAS  PubMed  Google Scholar 

  28. Di Salvatore M, Orlandi A, Bagala C, Quirino M, Cassano A, Astone A, et al. Anti- tumour and anti-angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line. Cell Prolif. 2011;44:139–46.

    Article  PubMed  Google Scholar 

  29. Li YY, Chang JW, Chou WC, Liaw CC, Wang HM, Huang JS, et al. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survivalfor non-small-cell lung cancers. Lung Cancer. 2008;59:180–91.

    Article  PubMed  Google Scholar 

  30. Ibrahim T, Mercatali L, Sacanna E, Tesei A, Carloni S, Ulivi P, et al. Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid. Cancer Cell Int. 2012;12(1):48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Rachner TD, Singh SK, Schoppet M, Benad P, Bornhauser M, Ellenrieder V, et al. Zoledronic acid induces apoptosis and changes the TRAIL/OPG ratio in breast cancer cells. Cancer Lett. 2010;28(1):109–16.

    Article  Google Scholar 

  32. Mani J, Vallo S, Barth K, Makarević J, Juengel E, Bartsch G, et al. Zoledronic acid influences growth, migration and invasive activity of prostate cancer cells in vitro. Prostate Cancer Prostatic Dis. 2012;15(3):250–5.

    Article  CAS  PubMed  Google Scholar 

  33. Kubista B, Trieb K, Sevelda F, Toma C, Arrich F, Heffeter P, et al. Anticancer effects of zoledronic acid against human osteosarcoma cells. J Orthop Res. 2006;24(6):1145–52.

    Article  CAS  PubMed  Google Scholar 

  34. Iguchi T, Miyakawa Y, Saito K, Nakabayashi C, Nakanishi M, Saya H, et al. Zoledronate-induced S phase arrest and apoptosis accompanied by DNA damage and activation of the ATM/Chk1/cdc25 pathway in human osteosarcoma cells. Int J Oncol. 2007;31(2):285–91.

    CAS  PubMed  Google Scholar 

  35. Tassone P, Tagliaferri P, Viscomi C, Palmieri C, Caraglia M, D'Alessandro A, et al. Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Br J Cancer. 2003;88(12):1971–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Romani AA, Desenzani S, Morganti MM, La Monica S, Borghetti AF, Soliani P. Zoledronic acid determines S-phase arrest but fails to induce apoptosis in cholangiocarcinoma cells. Biochem Pharmacol. 2009;78(2):133–41.

    Article  CAS  PubMed  Google Scholar 

  37. Koto K, Murata H, Kimura S, Horie N, Matsui T, Nishigaki Y, et al. Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agent. Oncol Rep. 2010;24(1):233–9.

    CAS  PubMed  Google Scholar 

  38. Liu SS, Wang XP, Li XB, Liang JY, Liu LL, Lu Y, et al. Zoledronic acid exerts antitumor effects in NB4 acute promyelocytic leukemia cells by inducing apoptosis and S phase arrest. Biomed Pharmacother. 2014;68(8):1031–6.

    Article  CAS  PubMed  Google Scholar 

  39. Karabulut B, Karaca B, Varol U, Muslu U, Cakar B, Atmaca H, et al. Enhancing cytotoxic and apoptotic effect in OVCAR-3 and MDAH-2774 cells with all-trans retinoic acid and zoledronic acid: a paradigm of synergistic molecular targeting treatment for ovarian cancer. J Exp Clin Cancer Res. 2010;29:102.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Porru M, Zappavigna S, Salzano G, Luce A, Stoppacciaro A, Balestrieri ML, et al. Medical treatment of orthotopic glioblastoma with transferrin-conjugated nanoparticles encapsulating zoledronic acid. Oncotarget. 2014;5(21):10446–59.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Hiraga T, Williams PJ, Ueda A, Tamura D, Yoneda T. Zoledronic acid inhibits visceral metastases in the 4T1/luc Mouse breast cancer model. Clin Cancer Res. 2004;10:4559–67.

    Article  CAS  PubMed  Google Scholar 

  42. Fromigue O, Lagneaux L, Body JJ. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res. 2000;15:2211–21.

    Article  CAS  PubMed  Google Scholar 

  43. Verdijk R, Franke HR, Wolbers F, Vermes I. Differential effects of bisphosphonates on breast cancer cell lines. Cancer Lett. 2007;246:308–12.

    Article  CAS  PubMed  Google Scholar 

  44. Cimini E, Piacentini P, Sacchi A, Gioia C, Leone S, Lauro GM, et al. Zoledronic acid enhances Vδ2 T-lymphocyte antitumor response to human glioma cell lines. Int J Immunopathol Pharmacol. 2011;24(1):139–48.

    Article  CAS  PubMed  Google Scholar 

  45. Nakazawa T, Nakamura M, Park YS, Motoyama Y, Hironaka Y, Nishimura F, et al. Cytotoxic human peripheral blood-derived γδT cells kill glioblastoma cell lines: implications for cell-based immunotherapy for patients with glioblastoma. J Neurooncol. 2014;116(1):31–9.

    Article  CAS  PubMed  Google Scholar 

  46. Fukai J, Koizumi F, Nakao N. Enhanced anti-tumor effect of zoledronic acid combined with temozolomide against human malignant glioma cell expressing O6-methylguanine DNA methyltransferase. PLoS One. 2014;9(8):e104538.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Biology Department, Ege University Medical School, Bornova, Izmir, Turkey

    Cigir Biray Avci, Cansu Caliskan Kurt, Ozgun Ozalp, Bakiye Goker, Zeynep Mutlu & Cumhur Gunduz

  2. Department of Molecular Biology and Genetics, Avrasya University Faculty of Science and Letters, Trabzon, Turkey

    Burcu Erbaykent Tepedelen

  3. Medical Biology Department, Pamukkale University Medical School, Denizli, Turkey

    Yavuz Dodurga & Levent Elmas

Authors
  1. Cigir Biray Avci
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cansu Caliskan Kurt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Burcu Erbaykent Tepedelen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ozgun Ozalp
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bakiye Goker
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zeynep Mutlu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yavuz Dodurga
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Levent Elmas
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Cumhur Gunduz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cigir Biray Avci.

Ethics declarations

Conflicts of interest

None

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Biray Avci, C., Kurt, C.C., Tepedelen, B.E. et al. Zoledronic acid induces apoptosis via stimulating the expressions of ERN1, TLR2, and IRF5 genes in glioma cells. Tumor Biol. 37, 6673–6679 (2016). https://doi.org/10.1007/s13277-015-4519-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-015-4519-3

Keywords

Search

Navigation